RE: Rns...27 Jan 2022 09:17
Amazing update.
Remember we have the IND, the recent application is to improve on the P1.
So often it’s the lowest invasive path and financials that will determine the patients preferred pathway….
‘ Brain tumor patients have limited options. The standard of care remains maximal surgical resection followed by concurrent chemo- and radiotherapy. These harsh treatments impose tremendous financial burden on patients and their families. Monthly costs for chemotherapy alone can exceed $20,000. Our hope is to offer a minimally invasive and non-toxic treatment alternative for these patients and their families. The entire team is eager to see if the tremendous results shown in the pre-clinical trial can be replicated in human subjects during this study.’
That statement alone imo sets a future revenue agenda.
Commencement of the P1 will be transformational and an efficacious result will likely set us up for a sale/JV.
I make no bones about it. I trade stocks to improve my average. I have averaged down here several times and set trades above my average to recycle. I have cancelled those today. Ignoring the ridiculous spread as the MM’s don’t want a rush because they likely don’t have stock I see this going on a srun soon and my sells would be imo selling the company short.
Obviously I will take some profit but not until well into double figures following this news!
So much to comment on in this update, resources in place, customers, Inc $bn one! Grants, which don’t come easy, FDA approval, networking capacity, computing software compatibility, working with TOP cancer institutions and with paediatrics which have huge loops to jump through! The list goes on. I am glad they are focusing on this tech. Even with our lowly mcap we are getting first mover advantage and an entry barrier.
All said though feet on ground. It’s a shareholder update, even objectively confirmation bias. Not new contracts. Not new revenues. Not new strategic alliances. So treat my comments as you will but if you are new looking in look at the potential. A huge multi million TAM and the competition, zero in the AI space! Just old tech!
Usual caveats
Trek